Search results
Showing 121 to 129 of 129 results for epilepsy
This guidance has been updated and replaced by NICE guideline NG217.
This guideline covers the care of women and their babies during labour and immediately after birth. It focuses on women who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.
View recommendations for NG235Show all sections
Sections for NG235
- Overview
- Recommendations
- Recommendations for research
- Rationale and impact
- Context
- Appendix A: Adverse outcomes for different places of birth
- Appendix B: Outcomes for different places of birth – by BMI at booking
- Appendix C: Outcomes for intravenous remifentanil patient-controlled analgesia (PCA) compared with intramuscular pethidine
We've updated our health inequalities web resource so that it maps NICE guidance to frameworks for children and young people. Dr Clare Morgan, director of implementation and partnerships explains how you can use the resource to ensure you're delivering effective care.
145,000 people in England to have further treatment choice for preventing migraine attacks.
NICE has for the first time recommended an oral treatment for preventing migraines.
Recent research has found that that the number of children being treated with epilepsy has fallen dramatically in the last decade.
NICE’s new guideline is the first to offer comprehensive information on neurological conditions to help non-specialist healthcare professionals to identify people who should be referred for specialist assessment and care.
More than one thousand neonatal admissions could be avoided per year by following NICE guidance
Regularly monitoring women who are pregnant with twins or triplets, to spot any possible complications, can lead to better outcomes for mothers and their babies, as highlighted in NICE’s impact report.
Around 10,000 people could benefit from new migraine drug as NICE says it's cost-effective
NICE has today (12 March 2020) published final draft guidance which recommends fremanezumab (also called Ajovy and made by Teva Pharmaceuticals) for preventing chronic migraine.
People growing older with learning disabilities should get regular health checks, says NICE
NICE says people growing older with learning disabilities need to have annual health checks to help them manage conditions that can quickly affect them as they grow older.